Discover
CVRX
CVRx, Inc.
5.50
2 x 3.96
2 x 6.48
bid
ask
+
0.36
7.00%
2 @ 04:00 PM
5.50 +0.00 (0.00%)
| Ytd | -22.54% | |
| 1y | -8.94% |
5.03
day range
5.53
4.37
52 week range
11.30
| Open | 5.12 | Prev Close | 5.14 | Low | 5.03 | High | 5.53 | Mkt Cap | 145.95M |
| Vol | 332.20K | Avg Vol | 324.50K | EPS | -2.01 | P/E | N/A | Forward P/E | -5.84 |
| Beta | 1.11 | Short Ratio | 5.33 | Inst. Own | 71.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 6.05 | 200-d Avg | 7.62 | 1yr Est | 18.17 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-01-23 | 2024-12 | -0.38 | N/A | N/A | N/A |
| 2024-10-29 | 2024-09 | -0.45 | -0.57 | -0.12 | -26.67% |
| 2024-07-29 | 2024-06 | -0.51 | N/A | N/A | N/A |
| 2024-07-29 | 2024-06 | -0.51 | -0.65 | -0.14 | -27.45% |
| 2024-04-30 | 2024-03 | -0.53 | N/A | N/A | N/A |
| 2024-04-30 | 2024-03 | -0.53 | -1.04 | -0.51 | -96.23% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-09 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-11-04 | Craig-Hallum | Upgrade | Buy | Buy |
| 2024-10-30 | Lake Street | Upgrade | Buy | Buy |
| 2024-10-30 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-10-30 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-10-23 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Profile
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-12-13 | BEHBAHANI ALI | Director | 316.00 | Conversion of Exercise of derivative security |
| 2023-10-15 | GALLE LIZ | Officer | 778.00 | Conversion of Exercise of derivative security |
| 2024-08-04 | HYKES KEVIN | Chief Executive Officer | 30.00K | Purchase |
| 2024-02-28 | JOHNSON & JOHNSON INNOVATION - JJDC, INC. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2023-09-17 | OASHEIM JARED | Chief Financial Officer | 15.45K | Conversion of Exercise of derivative security |
| 2024-03-24 | PALMER CRAIG E | Officer | 1.23K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Johnson & Johnson | 4.10M | 51.29M | 16.91% |
| 2024-09-29 | NEA Management Company, LLC | 2.37M | 29.63M | 9.77% |
| 2024-09-29 | Blackrock Inc. | 909.42K | 11.37M | 3.75% |
| 2024-09-29 | Vanguard Group Inc | 824.29K | 10.30M | 3.40% |
| 2024-09-29 | Parkman Healthcare Partners LLC | 682.90K | 8.54M | 2.81% |
| 2024-09-29 | Schonfeld Strategic Advisors Llc | 545.30K | 6.82M | 2.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 544.35K | 6.80M | 2.24% |
| 2024-10-30 | iShares Russell 2000 ETF | 338.54K | 4.23M | 1.40% |
| 2024-09-29 | College Retirement Equities Fund-Stock Account | 167.84K | 2.10M | 0.69% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 165.80K | 2.07M | 0.68% |
| 2024-09-29 | Trust for Professional Managers-Mairs & Power Small Cap Fund | 142.46K | 1.78M | 0.59% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 136.89K | 1.71M | 0.56% |